Cat. No.: HY-182019

HDAC11-IN-5

Customer Review

Based on 1 Customer Validation

HDAC11-IN-5 is a selective, potent and orally active HDAC11 inhibitor with an IC₅₀ of 0.021 μM. HDAC11-IN-5 increases fatty acylation levels of substrate SHMT2 in AML cells. HDAC11-IN-5 induces apoptosis, G1 phase cell cycle arrest, ferroptosis, ROS production and terminal myeloid differentiation in AML cells. HDAC11-IN-5 demonstrates anti-tumor potency in an MLL-AF9-induced mouse AML model. HDAC11-IN-5 can be used for the research of cancer, such as acute myeloid leukemia.

For research use only. We do not sell to patients.

Purity: 98.25%
Formula: C₂₄H₂₅Cl₂F₃N₄O₂
Molecular Weight:529.38

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

HDAC11-IN-5 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HDAC11

0.021 μM (IC₅₀)

SHMT2

All HDAC Isoforms :

All SHMT Isoforms :

SHMT1
SHMT2

In Vitro

HDAC11-IN-5 (Compound 25) potently inhibits purified HDAC11 protein with an IC₅₀ of 0.021 ± 0.005 μM, and shows no significant inhibition of HDAC1, HDAC6, HDAC7, or HDAC8 at concentrations up to 10 μM^[1].
HDAC11-IN-5 (96 h) potently inhibits proliferation of U937, OCI-AML2, THP-1, and MOLM13 AML cell lines with IC₅₀ values of 6.3 μM, 5.7 μM, 5.4 μM, and 6.7 μM, respectively^[1].
HDAC11-IN-5 (10-20 μM; 6 h) selectively inhibits intracellular HDAC11 in U937 AML cells, as shown by increased SHMT2 fatty acylation at 10 μM for 6 h and no significant changes in histone H3 or α-tubulin acetylation at 20 μM for 6 h^[1].
HDAC11-IN-5 (8 μM; 48 h) strongly induces apoptosis in U937 and OCI-AML2 AML cells^[1].
HDAC11-IN-5 (8 μM; 48 h) induces G1-phase cell cycle arrest in U937 AML cells^[1].
HDAC11-IN-5 (8 μM; 48 h) promotes myeloid differentiation of U937 AML cells, as shown by increased CD14 and CD11b expression^[1].
HDAC11-IN-5 (8 μM; 48 h) induces ferroptosis in U937 AML cells, as shown by increased lipid peroxidation, cellular ROS, and intracellular Fe²⁺ levels^[1].
HDAC11-IN-5 (5-20 μM; 96 h) exhibits strong synergistic antiproliferative activity with ivosidenib in U937, OCI-AML2, and MLL-AF9 mouse AML cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

U937 AML cells
Concentration:

10 μM (SHMT2 fatty acylation analysis); 20 μM (histone H3 and α-tubulin acetylation analysis)
Incubation Time:

6 h
Result:

Significantly increased fatty acylation levels of SHMT2 (a specific HDAC11 substrate) at 10 μM for 6 h.
Had negligible effects on acetylation levels of histone H3 (a class I HDAC substrate) and α-tubulin (an HDAC6 substrate) at 20 μM for 6 h.

Apoptosis Analysis^[1]

Cell Line:

U937, OCI-AML2 AML cell lines
Concentration:

8 μM
Incubation Time:

48 h
Result:

Significantly induced apoptosis in both U937 and OCI-AML2 cells.

Cell Differentiation Assay^[1]

Cell Line:

U937 AML cells
Concentration:

8 μM
Incubation Time:

48 h
Result:

Significantly increased expression of the myeloid differentiation markers CD14 and CD11b in U937 cells, with a stronger effect than FT895.

Parmacokinetics

Species	Dose	Route	T_1/2	AUC_0-∞	V_ss	CL	T_max	C_max	F
Mice^[1]	5 mg/kg	i.v.	3.74 h	613 ng·h/mL	14.87 L/kg	136 mL/min/kg	/	/	/
Mice^[1]	50 mg/kg	p.o.	2.39 h	1273 ng·h/mL	/	/	0.25 h	812 ng/mL	20.8 %

In Vivo

HDAC11-IN-5 (Compound 25) (50 mg/kg; i.g.; once daily; 14 days) reduces peripheral blood leukemic cell burden and significantly extends survival in an MLL-AF9-induced AML mouse model, with enhanced efficacy when combined with Ivosidenib (HY-18767)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (6-week-old female, 20-22 g, tail vein injection of 1×10⁵ MLL-AF9-GFP+ leukemic cells)^[1]
Dosage:

50 mg/kg
Administration:

I.g.,; once daily; 14 days
Result:

Reduced the percentage of GFP⁺ leukemic cells in peripheral blood.
Significantly extended the survival of AML mice compared to vehicle control.
Reduced the percentage of GFP⁺ leukemic cells when combined with ivosidenib, with greater survival extension than either agent alone.
Caused no significant body weight loss prior to the moribund stage.

Chemical Information

Appearance Solid
Molecular Weight 529.38
Formula C₂₄H₂₅Cl₂F₃N₄O₂
Color Light brown to yellow
SMILES

O=C(C1=CC=CC2=C1C=C(C#CC3=CC=CC(C(F)(F)F)=C3)N2CCN4CCNCC4)NO.Cl.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (188.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8890 mL

9.4450 mL

18.8900 mL

5 mM

0.3778 mL

1.8890 mL

3.7780 mL

10 mM

0.1889 mL

0.9445 mL

1.8890 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chai Q, et al. Discovery of a Hydroxamic Acid-Based HDAC11 Isoform-Selective Inhibitor with Oral Anti-AML Potency. J Med Chem. 2026;69(6):6816-6834. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8890 mL	9.4450 mL	18.8900 mL	47.2251 mL
	5 mM	0.3778 mL	1.8890 mL	3.7780 mL	9.4450 mL
	10 mM	0.1889 mL	0.9445 mL	1.8890 mL	4.7225 mL
	15 mM	0.1259 mL	0.6297 mL	1.2593 mL	3.1483 mL
	20 mM	0.0945 mL	0.4723 mL	0.9445 mL	2.3613 mL
	25 mM	0.0756 mL	0.3778 mL	0.7556 mL	1.8890 mL
	30 mM	0.0630 mL	0.3148 mL	0.6297 mL	1.5742 mL
	40 mM	0.0472 mL	0.2361 mL	0.4723 mL	1.1806 mL
	50 mM	0.0378 mL	0.1889 mL	0.3778 mL	0.9445 mL
	60 mM	0.0315 mL	0.1574 mL	0.3148 mL	0.7871 mL
	80 mM	0.0236 mL	0.1181 mL	0.2361 mL	0.5903 mL
	100 mM	0.0189 mL	0.0945 mL	0.1889 mL	0.4723 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

HDAC11-IN-5

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Osteogenesis Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

Alkyne Compound Library

All HDAC Isoforms

All SHMT Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

HDAC11-IN-5 Related Classifications

HY-182019 Related Classifications